Kamada Ltd. shares rise 1.15% intraday after Advanz Pharma and Alvotech receive European approval for Mynzepli®.

Kamada Ltd. rose 1.15% in intraday trading, with Advanz Pharma and Alvotech receiving European approval for Mynzepli® (aflibercept) for the treatment of various retinal diseases, including neovascular (wet) age-related macular degeneration (AMD). The approval is based on comprehensive analytical, non-clinical, and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMD.